摘要
目的:研究慢性乙型肝炎(CHB)患者抗病毒治疗前后外周血HBV特异性细胞毒性T淋巴细胞(CTL)的变化及其临床意义。方法:选择我院2016年7月至2018年1月纳入的90例CHB患者作为A组,51例非病毒性肝病患者作为B组,另选择同一时间体检的80例健康者作为C组,均检测其外周血HBV特异性CTL、HBV DNA、丙氨酸氨基转移酶(ALT)变化。结果:A组患者治疗后的HLA-A2^+检出率低于治疗前,但治疗前后的HLA-A2^+检出率均高于B、C组(P<0.05)。A组患者治疗前后的HBV特异性CTL阳性率与B、C组相比差异有统计学意义(P<0.05),其中HLA-A2^-组的阳性率高于HLA-A2^+组(P<0.05);但B、C组的HLA-A2^-组的阳性率与HLA-A2^+组差异无显著性(P>0.05)。A组治疗前后的HBV DNA、ALT水平与B、C组相比差异有显著性(P<0.05),除C组的HBV DNA水平之外,各组HLA-A2^-的水平与HLA-A2^+相比差异有显著性(P<0.05)。结论:慢性HBV感染患者治疗前后的外周血HBV特异性CTL存在较大差异,可为临床预后评估的指标。
Objective:To study the changes of peripheral blood specific cytotoxic T lymphocytes(CTL), in chronic hepatitis B CHB patients underwent the antiviral therapy.Methods:Ninety cases CHB patients treated from July 2016 to January 2018 in our hospital were selected as group A;51 non-viral liver disease patients were selected as group B;80 healthy checkups were selected as group C.The peripheral blood specific CTL, HBV DNA and alanine aminotransferase(ALT) were detected.Results:After treatment, the detection rate of HLA-A2^+ in group A was lower than before;before and after treatment, the detection rate of HLA-A2^+ in group A was higher than group B and group C(P<0.05);before and after treatment, the positive specific CTL rate in group A was significantly different from group B and group C(P<0.05);besides, the positive HLA-A2^- rate was higher than the HLA-A2^+ rate(P<0.05);the positive HLA-A2^- rate in group B and group C was not significantly different from the HLA-A2^+ rate(P>0.05);before and after treatment, the HBV DNA and ALT contents in group A were significantly different from group B and group C(P<0.05);except for HBV DNA contents in group C, the HLA-A2^- and HLA-A2^+ contents among groups were significantly different(P<0.05).Conclusion:Before and after treatment, the peripheral blood specific CTL of CHB patients was significantly different, which can be considered as the important indicators of clinical prognosis assessment.
作者
黄金华
崔显念
姜宜
黄敏
余冰
HUANG Jin-hua;CUI Xian-nian;JIANG Yi(Laboratory Department,TCM Section Of The Central Hospital Of Enshi Autonomous Prefecture(Enshi Hubei,445000) China)
出处
《中西医结合肝病杂志》
CAS
2019年第3期225-227,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
湖北省卫生计生委面上课题项目(No.WJ2017M049)